March 16 (Reuters) – Structure Therapeutics said its oral obesity drug aleniglipron delivered up to 16.3% weight loss, when compared with a placebo after 44 weeks of treatment in a mid‑stage study.
(Reporting by Sahil Pandey and Puyaan Singh in Bengaluru; Editing by Sahal Muhammed)
